- New
8.5mg Zenrelia for Dogs - Per Tablet
961206
8.5mg Zenrelia for Dogs
8.5mg Zenrelia for Dogs is a prescription-only medication used to help manage the symptoms of atopic dermatitis in dogs (Atopy). Atopic dermatitis is a common, long-term skin condition that can significantly affect a dog’s comfort and overall wellbeing. Zenrelia is formulated to reduce the itching and inflammation that often accompany this condition, providing effective relief and improving quality of life.
Zenrelia contains an active ingredient that targets specific pathways in the immune system responsible for the itching and inflammation seen in atopic dermatitis. Unlike traditional anti-inflammatory drugs that act broadly, 8.5mg Zenrelia works by selectively blocking signals in the immune system that lead to the itch response.
When a dog with atopic dermatitis encounters an allergen, the immune system mistakenly identifies it as harmful and triggers a reaction. This process releases chemical messengers that cause the skin to itch and become inflamed. Zenrelia interferes with these signals, reducing the sensation of itching and calming the inflammation.
The 8.5mg strength is designed for small to medium-sized dogs and allows for accurate dosing according to weight. By interrupting the itch-scratch cycle, Zenrelia not only eases discomfort but also reduces the risk of further skin damage and secondary infections. Dogs that are less itchy are less likely to scratch and bite at their skin, which means healing can take place more effectively.
VETERINARY PRESCRIPTION REQUIRED
Product Features
- Pack Size: - Sold Individually
- Target Animal: - Dog (Canine)
- Related Condition: - allergic and atopic dermatitis in dogs
- Pet Prescription Required?: - Yes
- Active Ingredient: - ilunocitinib
- Product Name: - 8.5mg Zenrelia Tablet for Dogs
More Information
Description
What is Atopic Dermatitis in Dogs?
Atopic dermatitis is an allergic skin disease that is frequently diagnosed in dogs. It occurs when a dog’s immune system overreacts to environmental allergens such as pollen, mould spores, house dust mites, or certain grasses. Dogs with atopic dermatitis have skin that becomes inflamed, itchy, and irritated due to this hypersensitive immune response.
The condition is often genetic and can be seen in a wide variety of breeds, although certain breeds are more prone. Signs usually appear in young adult dogs, but symptoms can continue or worsen over time if not managed effectively.
Typical symptoms of atopic dermatitis include:
- Persistent itching and scratching
- Licking or chewing at the paws, legs, or abdomen
- Red, inflamed patches of skin
- Ear infections or head shaking due to itchy ears
- Hair loss or thinning fur in affected areas
- Thickened or darkened skin over time
Atopic dermatitis can have a seasonal pattern if triggered by allergens like pollen, or it may persist year-round if caused by indoor triggers. The discomfort can lead to secondary infections of the skin and ears if left untreated, making early management very important.
Atopic dermatitis is a chronic condition, and 8.5mg Zenrelia forms one part of a long-term management plan. Your Vet may also recommend additional treatments such as medicated shampoos, topical creams, dietary adjustments, or allergy testing. Managing the dog's environment to reduce exposure to allergens may also be advised.
As with any medication, side effects can occur. Zenrelia is generally well tolerated, but dogs should be observed for any unusual changes in behaviour, appetite, or overall health. If concerns arise, it is essential to contact a veterinarian promptly.
Because atopic dermatitis is not curable, the goal of treatment is to manage the symptoms effectively. Zenrelia provides a targeted way of reducing itching and inflammation, allowing dogs to live more comfortably. Consistency in treatment and regular veterinary care are vital to keeping the condition under control.
You may also like
100 x 5.4mg Apoquel Tablets - Box of 100
5.4mg Apoquel Tablets are the latest treatment for acute and chronic pruritus (itching) in dogs. VET PRESCRIPTION REQUIRED
4.8mg Zenrelia for Dogs - Per Tablet
4.8mg Zenrelia for Dogs
Zenrelia 4.8mg is a once-daily, tablet formulated for dogs aged twelve months and older to manage the itch and inflammation linked to allergic and atopic dermatitis. The active ingredient, ilunocitinib, acts as a non-selective Janus kinase (JAK) inhibitor. It works by interrupting key inflammatory signalling pathways that trigger itch sensations and skin irritation. Zenrelia is not a corticosteroid or antihistamine, but instead targets the underlying immune-mediated mechanisms that fuel pruritus and lesion formation.
Since ilunocitinib is rapidly absorbed and has a short half-life, the tablet begins to provide relief swiftly following administration and clears from the dog’s system within about 24 hours if treatment is paused. This pharmacokinetic profile offers dosing flexibility, permitting treatment to be initiated or stopped as needed, for instance, during diagnostic food trials without lingering drug accumulation.
4.8mg Zenrelia is designed for convenience and compliance. It can be administered with or without food and requires no loading dose or tapering phase. The scoring on the tablets in multiple strengths enables precise dosing from as low as approximately 0.6 mg per kilogram up to 0.8 mg per kilogram (0.27–0.36 mg per pound). This makes Zenrelia adaptable for dogs of different sizes and weight classes.
In clinical trials involving several hundred dogs with allergic or atopic dermatitis, Zenrelia demonstrated rapid reduction in itch scores and skin lesion severity, with outcomes comparable to or exceeding those of existing JAK inhibitors. Visual and numerical assessments showed notable improvements in both itching and inflammation within weeks of treatment commencement. The repeat-daily dosing maintained this effect over the longer term, supporting skin health and owner satisfaction.
VETERINARY PRESCRIPTION REQUIRED
- New
6.4mg Zenrelia for Dogs - Per Tablet
6.4mg Zenrelia is a once-daily, orally administered tablet containing ilunocitinib, a Janus kinase (JAK) inhibitor indicated for dogs from 12 months of age and weighing at least 3kg. It is formulated as a small, unflavoured film-coated tablet designed for ease of administration with or without food, with consistent dosing recommended at the same time each day.
Zenrelia works by inhibiting Janus kinase pathways involved in the inflammatory and pruritic signalling cascade. By targeting these pathways, Zenrelia reduces the biochemical processes that result in the characteristic itch and inflammation of allergic and atopic dermatitis. Following oral administration, it is rapidly absorbed, with visible improvements often appearing within 24 hours. While some dogs respond immediately, a full assessment of response should wait at least one week, with most showing notable improvement in itch and skin condition by two to four weeks.
Zenrelia 6.4mg is appropriate for use from the first veterinary consultation through diagnostic work-up and into long-term maintenance. Its simple, once-daily dosing implies that caregivers can begin treatment before a full diagnosis of atopic dermatitis, helping manage symptoms while underlying causes are explored and addressed.
VETERINARY PRESCRIPTION REQUIRED
- New
15mg Zenrelia for Dogs - Per Tablet
15mg Zenrelia for Dogs
15mg Zenrelia for Dogs is a prescription medicine used to help manage the itch and skin inflammation associated with allergic skin disease, including atopic dermatitis (atopy). Zenrelia is intended for dogs that have been examined by a veterinary surgeon and diagnosed with an allergic condition. Zenrelia 15mg is used as part of a wider care plan that may include parasite control, skin and ear care, environmental changes, and nutrition.
How Zenrelia for Dogs works
Zenrelia acts on the pathways that drive itch and inflammation during an allergic flare. In dogs with atopy, the immune system reacts strongly to otherwise harmless substances such as pollen, house dust mites, moulds, or other environmental allergens. This reaction releases chemical messengers that signal itch, redness, heat, and swelling in the skin. Zenrelia Tablets help to reduce these signals. By moderating the activity of key immune messengers and the cells that release them, the medicine lowers the intensity of the itch response and helps calm inflamed skin. As the impulse to scratch and lick reduces, the skin surface has a better chance to recover, which in turn helps to limit further irritation.
Zenrelia does not sedate dogs and it does not mask pain. Its role is to target the allergic component of skin disease. Because every dog and every allergy profile is different, your vet will assess how Zenrelia is working for your dog over time and may adapt the plan, including adding topical products or adjusting other treatments. If your dog’s symptoms change, or if you notice new signs such as ear headshaking, paw chewing, hot spots, or disturbed sleep, contact your vet for review.
- New